Article Details

BenevolentAI secures $2bn valuation after raising $115mn in funding

Retrieved on: 2018-04-19 04:03:45

Tags for this article:

Click the tags to see associated articles and topics

BenevolentAI secures $2bn valuation after raising $115mn in funding. View article details on hiswai:

Excerpt

<div>Other AI-powered drug developers include Scotland's Exscientia and US -based firms Berg, Numerate, twoXAR, Atomwise and <b>InSilico Medicine</b>. It uses software to understand the cause of disease and generate drug candidates at scale, and has created a bioscience machine brain to help discover new ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up